Table 2. Predictors considered and selected for the final models.

	Overall survival		Recurrence-free survival
Final model	Global P value: 2.583e-08		Global P value: 6.005e-06
	Survival probability is 1 at baseline, which is the date of surgery		Survival probability is 1 at baseline, which is the date of surgery
	Predictor variables	Pooled coefficient	Predictor variables	Pooled coefficient
	1. Bilirubin (>35 μmol/L) pre-hepatectomy	2.31	1. Bilirubin (>35 μmol/L) pre-hepatectomy	1.46
	2. Extrahepatic Metastasis detected on PET-scan	0.41	2. CEA pre-hepatectomy (>200 ng/mL)	0.51
	3. CEA pre-hepatectomy (>200 ng/mL)	0.25	3. Neoadjuvant treatment for CRLM	0.43
	4. Neoadjuvant treatment for CRLM	0.28	4. Extrahepatic Metastasis detected on PET-scan	0.30
	5. CRC N stage	0.25	5. CRC N stage	0.30
	6. KRAS mutation status	0.18	6. KRAS mutation status	0.18
	7. Charlson Comorbidity Score	0.17	7. Charlson Comorbidity Score	0.12
	8. CRLM largest tumor diameter	0.06	8. CRLM largest tumor diameter	0.06
Other non-0 predictors from LASSO regression excluded from the final model	1. Adjuvant Chemotherapy following CRLM resection		1. Adjuvant Chemotherapy following CRLM resection
	2. Number of CRLM		2. Number of CRLM
	3. CRLM lymphovascular invasion		3. Number CRLM >3 (Nordlinger)
	4. Largest CRLM tumor diameter on PET-scan		4. CRLM lymphovascular invasion
	5. CRC # of lymph nodes		5. Bilobar CRLM on PET-scan
	6. CRC lymphovascular invasion		6. CRC lymphovascular invasion
	7. CRC resection margin		7. CRC resection margin
	8. Disease free interval >1 year (Fong Score)		8. Disease Free interval >1 year (Fong Score)
	9. Laparoscopic hepatectomy		9. Laparoscopic hepatectomy

LASSO, Least Absolute Shrinkage and Selection Operator; PET, positron emission-tomography; CEA, carcinoembryonic antigen; CRLM, colorectal liver metastases; CRC, colorectal cancer.